{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-018763","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.636984+00:00","generated_at":"2026-06-05T20:41:50.725185+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relay Therapeutics Q4 2023 net loss $83.5M; cash $750M funds into H2 2026","bullets":["Net loss $83.5M in Q4 2023 ($0.67 per share) vs $67.5M loss in Q4 2022.","Full year 2023 net loss $342.0M ($2.79 per share) vs $290.5M in 2022.","Cash, cash equivalents and investments $750.1M at Dec 31, 2023; expected to fund operations into H2 2026.","Completed enrollment in RLY-2608 600mg + fulvestrant dose expansion; initiated additional cohorts and triplet with ribociclib.","Deprioritized further clinical development of RLY-5836."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-018763","json":"https://secwatch.observer/filing/0000950170-24-018763.json","markdown":"https://secwatch.observer/filing/0000950170-24-018763.md","text":"https://secwatch.observer/filing/0000950170-24-018763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/0000950170-24-018763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/rlay-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T20:41:50.725185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f77ad0dab0b7c194d52192552a35dba0f5da6bd","claim":"Relay Therapeutics, Inc. reported the full year 2023 results: revenue Revenue was $25.5 million for the full year 2023, net income Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79, EPS $2.79.","evidence_excerpt":"Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/0000950170-24-018763-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2023"},{"label":"Revenue","value":"Revenue was $25.5 million for the full year 2023"},{"label":"Net income","value":"Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79"},{"label":"EPS","value":"$2.79"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"79be9e1beda19c4f0aa116b77cadf6ef612859a0","claim":"Relay Therapeutics, Inc. reported the fourth quarter of 2023 results: net income Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67, EPS $0.67.","evidence_excerpt":"Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/0000950170-24-018763-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Net income","value":"Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67"},{"label":"EPS","value":"$0.67"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}